CD4⁺FoxP3⁺ Regulatory T Cells from Gxi2⁻/⁻ Mice Are Functionally Active In Vitro, but Do Not Prevent Colitis

Yu-Yuan C. Götlind¹*, Sukanya Raghavan¹, Paul W. Bland¹,², Elisabeth Hultgren Hörnquist³

¹Department of Microbiology & Immunology, Institute of Biomedicine, Mucosal Immunology and Vaccine Center, University of Gothenburg, Gothenburg, Sweden, ²University of Bristol, Clinical Veterinary Science, Bristol, United Kingdom, ³School of Health and Medical Sciences, Örebro University, Örebro, Sweden

Abstract

Background: Mice deficient in the inhibitory G protein subunit Gxi2 spontaneously develop a T helper 1 dominated colitis. We examined whether a defect in CD4⁺FoxP3⁺ regulatory T cells (Treg) underpins the pathogenesis of colitis in the Gxi2⁻/⁻ (Gxi2-deficient) colitis model.

Methodology/Principal Findings: Using flow cytometry, we found that thymus and colonic lamina propria, but not spleen and mesenteric lymph nodes, of colitic Gxi2⁻/⁻ mice contained increased frequencies of Treg, whereas FoxP3 expression intensity was similar in Gxi2⁻/⁻ compared to Gxi2⁺/+ or Gxi2⁺/+ wild type (WT) mice. The frequency of CD4⁺FoxP3⁺ T cells expressing CD103 was significantly increased in Gxi2⁻/⁻ compared to WT mice. Treg in colons from WT mice clustered in the T cell areas of colonic lymphoid patches (CLP), with relatively few Treg in the lamina propria, as demonstrated by immunohistochemistry. In Gxi2⁻/⁻ mice, CLP were not observed but lamina propria Treg were increased in number and frequency within the CD4⁺ infiltrate, compared to WT mice. Using an in vitro co-culture system and flow cytometric analysis of cell division we could demonstrate that the in vitro suppressive function of WT and Gxi2⁻/⁻ CD4⁺FoxP3⁺ regulatory T cells (WT-Treg and KO-Treg) was indistinguishable, but that T effector cells (CD4⁺CD25⁺ T cells) from Gxi2⁻/⁻ mice were less readily suppressed than WT effectors (WT-Teff) by Treg from either source. However, neither WT nor Gxi2⁻/⁻ Treg was able to suppress colitis induced by adoptive transfer of Gxi2⁻/⁻ T effector cells (KO-Teff) to Rag2⁻/⁻ recipients. The enhanced inflammatory activity of Gxi2⁻/⁻ T effectors was accompanied by increased expression of an effector/memory T cell phenotype and increased cytokine secretion, especially IL-4, IL-6 and IFN-γ.

Conclusions: There is an increased frequency of Gxi2⁻/⁻ Treg in the colon, and they demonstrate no endogenous functional defect. However, Gxi2⁻/⁻ T effector cells are dramatically less susceptible to suppression in vitro, and in vivo, despite increased effective numbers of Treg, they cannot prevent disease.

Introduction

The mucosal immune dysregulation which results in chronic inflammatory bowel disease (IBD) has been evaluated using several chemically-induced, T cell transfer and spontaneous mouse models of colitis. Untreated Gxi2⁻/⁻ mice on a 129SvEv background spontaneously develop colitis [1,2,3]. The inflammation is restricted to the large intestine, resembling the pathology seen in human ulcerative colitis (UC) with crypt distortion, loss of mucus producing goblet cells, and abscess formation together with erosion and ulcerations of the mucosa [1,2,3].

The development of colitis in the Gxi2⁻/⁻ mouse model is dependent on the presence of an enteric microflora (unpublished observations) and is characterized by a Th1 CD4⁺ T cell response, with increased production of IFN-γ, together with increased levels of IL-1, IL-6 and TNF-α in inflamed tissue [1,2,4,5]. The lack of Gxi2 results in functional disorders in epithelial cells [5], professional antigen-presenting cells [6], B cells [2,4,6] and CD4⁺ T cells [1,3,7,8,9] and points to multiple requirements for Gxi2 in mucosal immune regulation, but the underlying molecular mechanisms involving Gxi2 have not been defined.

Mucosal tolerance to environmental and food antigens is essential to prevent exacerbated immune reactions that can cause allergic diseases and chronic inflammation, and it has long been recognized that the gut is an important site for the induction of tolerance [10]. Peripheral immune tolerance is mediated by several mechanisms, including anergy; deletion; ignorance; or suppression of effector T cell (Teff) function by different populations of regulatory T cells (Treg) [11]. There are two subsets of Treg: natural Treg (nTreg), which develop in the thymus; and inducible Treg (iTreg), which are derived from naïve CD4⁺ T cells in the periphery. Inducible Treg comprise type 1 regulatory T cells (Tr1), which are induced by IL-10 [12] and T helper 3 (Th3) cells, which are induced by TGFB [13]. Treg utilize a variety of mechanisms to suppress the immune response. Generally, nTreg are believed to suppress by a cell–cell contact-
dependent mechanism in vitro (possibly by granzyme or perforin-mediated cytotoxicity or by cAMP), while their regulatory effects in vivo are assumed to be mainly cytokine-mediated [14,15].

The development, function, and homeostasis of Treg are controlled by the forkhead family transcription factor, Foxp3 [16,17,18]. Mutations in the gene encoding Foxp3/FOXP3 have been identified in both mice and humans [16,19]. Patients with mutations in FOXP3 develop a severe, fatal systemic autoimmune disorder, Immune Dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome [19]. Experiments using adoptive transfer of effector and regulatory T cell populations into immunodeficient mice indicate a crucial role for Treg in maintaining mucosal immune homeostasis [20,21], suggesting that dysfunction of Treg may be a contributory factor in the pathogenesis of human IBD.

In this study, we address the hypothesis that colitis in Gst2−/− mice is a consequence of a qualitative or quantitative defect in CD4+FoxP3+ regulatory T cells (Treg). The data show that although Treg from Gst2−/− mice are functional in vitro, and are present at enhanced frequency within the CD4+ infiltrate in colitis, they are unable to prevent disease caused by endogenously activated Gst2−/− effector T cells, the latter being significantly more resistant to suppression by either wild type or Gst2−/− Treg.

Materials and Methods

Ethics statement

All animal procedures were carried out under local and national ethical guidelines (Swedish Board of Agriculture) and were approved by the regional ethical committee, Gothenburg Administrative Court of Appeal, with the ethical approval ID 79-2008.

Mice

Gst2−/− (Gst2−/−) mice on a pure 129SvEv background were bred and maintained under specific pathogen-free conditions in microisolator cages with filtered air at the Department of Experimental Biomedicine, University of Gothenburg. Heterozygous Gst2+/− males were bred with heterozygous females, and the offspring were genotyped by polymerase chain reaction (PCR) analysis using genomic DNA from the tail. Homozygous Gst2−/− mice on this background develop a lethal colitis between the age of 5 and 8 weeks. In this study, mice were euthanized at 4–5 weeks (pre-colitic) or 5–9 weeks (colitic) and the absence/presence of colitis was confirmed post mortem. The experiments included both male and female mice as gender differences in clinical disease or immune parameters have not been found [7]. Both homozygous wild-type (WT) Gst2+/+ and heterozygous (Gst2+/−) mice were used as controls in the study (collectively referred to here as “WT mice”). RAG2−/− mice on a 129SvEv background (a kind gift from F. Powrie, Univ. of Oxford) were bred homozygous, and were used as recipients in our cell transfer model.

Media and antibodies

Fetal calf serum (FCS), 2-mercaptoethanol and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO). Fixation/permeabilization, sections were incubated with rat IgG2a anti-mouse Foxp3, or with rat IgG2a isotype control, followed by detection using goat anti-rat IgG Alexa Fluor 568. The samples were then incubated with rat anti-mouse CD4, followed by goat anti-rat IgG Alexa Fluor 488. The slides were mounted in 4′,6-diamidino-2-phenylindole (DAPI)-containing mounting medium (Molecular Probes-Invitrogen) and visualized with a Zeiss Axioskop 2 microscope (Carl Zeiss Imaging, Thornwood, NY) and analyzed by Axiovision 4.5 software (Carl Zeiss Imaging) or Leica DFC 480 (Leica Microsystems GmbH, Germany). CD4+ cells and CD4+FoxP3+ cells were counted, using Image J (Image Processing and Analysis in Java, National Institutes of Health, U.S.A.), at 3–5 sites of the mucosa in distal colons from four colitic Gst2−/− mice and 4 WT controls; and at least one colonic lymphoid patch (CLP) in each of four WT control mice.

Preparation of cell suspensions

Single cell suspensions were prepared from the whole thymus, spleen or mesenteric lymph nodes (MLN) as previously described [1,7]. Splenic erythrocytes were lysed with ammonium chloride and cells were then washed in phosphate-buffered saline (PBS) containing 1% heat inactivated fetal calf serum (FCS). For isolation of colonic lamina propria lymphocytes (LPL), dissected colons were washed free of fecal contents by flushing with saline. They were then opened longitudinally, washed extensively in Hank’s Balanced Salt Solution without Calcium and Magnesium (CMF-HBSS) supplemented with 15 mM HEPES and incubated for 5×15 min at 37°C, in CMF-HBSS containing 5 mM EDTA to remove epithelial cells and intraluminal lymphocytes. The remaining tissue was incubated for 15 min in RPMI 1640 containing 15 mM HEPES and 10% heat inactivated FCS, followed by three successive 60 min incubations in Liberase/blendzyme 3 (0.2 Wunsch units/ml, Roche Applied Science, Indianapolis, IN) in RPMI 1640 medium+GlutaMAX I containing 15 mM HEPES and 20% heat inactivated horse serum, yielding LPLs.

Flow cytometry

Single cell suspensions of 1×10^6 cells/30 μl were incubated on ice for 10 min with unconjugated anti-CD16/CD32 and then for 30 min with: anti-CD4-PE or -FITC; anti-CD3e-PE; anti-CD25-APC; and anti-Foxp3-PE or -FITC.
For intracellular staining, cells were first permeabilized using Fixation/Permeabilization solution. Cells were then acquired on a BD LSRII flow cytometer (BD Biosciences, San Jose, CA), and the data analyzed using the Flow-Jo software (Tree Star Inc., San Carlos, CA).

**Cell fractionation**

Splenitic CD4+ cells were partially purified by negative selection on AutoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany), following the manufacturer’s instructions, using the mouse CD4+ T cell isolation kit (Miltenyi Biotec). Cells were then labeled with fluorochrome-conjugated CD4-PB, CD25-APC, CD3e-PE in PBS supplemented with 2% FCS and 2 mM EDTA, washed and subsequently sorted into CD25+ and CD25− subpopulations using a FACSaria® (BD Biosciences). Purity of the sorted cells (CD3+CD25+CD25− or CD3+CD4−CD25−) ranged from 95% to 98%. The CD25+ and CD25− populations contained 89.3±6.9% (n = 9) and 6.3±1.8% (n = 9) (Gtα2−/− mice) or 91.0±6.0% (n = 11) and 4.3±1.4% (n = 6) (WT mice) FoxP3+ lymphocytes, respectively.

**Macroscopic scoring of colitis**

Colonic pathology was macroscopically scored in a blinded fashion by two independent observers and graded for the following parameters: thickness (0–2), stiffness (0–3), edema (0–3) and visible ulcerations (0–1), with a total maximum score of 9 [22].

**Adoptive transfer**

Freshly sorted splenic CD4+CD25+ (Treg) and CD4+CD25− cells (Teff), either 4×10⁵ Teff only, or co-transferred with 1×10⁵ Treg, from colitic Gtα2−/− and WT mice were adoptively transferred into 129SvEv RAG2−/− mice by i.p. injection. RAG2−/− mice on this background are resistant to colitis induction by WT effector T cells in the absence of *H. hepaticus* infection [23].

**Table 1.** Frequency of FoxP3+ T cells in CD4+, CD4+CD25+ and CD8− subpopulations from mesenteric lymph nodes (MLN), as determined by flow cytometry.

| Subpopulation | Mean % ± SD of FoxP3+ | Range |
|---------------|-----------------------|-------|
| CD4+          |                       |       |
| early colitic mice | n = 7 | 10.7±2.5 | (7.34–13.3) |
| control mice †  | n = 7 | 9.0±1.0 | (7.84–10.2) |
| CD4+CD25+     |                       |       |
| early colitic mice | n = 7 | 11.4±1.6 | (8.84–12.9) |
| control mice † † | n = 7 | 9.1±1.4 | (7.76–11.9) |
| CD4+CD25−     |                       |       |
| early colitic mice | n = 7 | 81.0±8.7 | (71.1–94.6) |
| control mice † | n = 7 | 82.0±11.9 | (66.0–95.1) |
| CD8−          |                       |       |
| early colitic mice | n = 7 | 79.2±5.7 | (73.2–87.8) |
| control mice † † | n = 7 | 91.2±2.2 | (88.8–93.4) |
| CD8+          |                       |       |
| early colitic mice | n = 7 | 1.6±1.4 | (0.29–3.73) |
| control mice † | n = 7 | 1.2±1.0 | (0.29–2.46) |
| colitic mice | n = 7 | 0.6±0.3 | (0.26–0.96) |
| control mice † † | n = 7 | 0.4±0.2 | (0.29–0.75) |

†: 4–6 weeks old mice,
† †: 7–9 weeks old mice.

![Figure 1. Frequency and intensity of expression of FoxP3 in CD4+ T cells in central, peripheral and mucosal lymphoid tissue. A. Frequencies of FoxP3+ cells in gated CD4+ T lymphocytes in colitic Gtα2−/− mice were compared to age-matched control mice, (n=6 in each group) as determined by FACS analysis. Each symbol represents one mouse and the mean of each group is indicated by a line. Results are shown from at least three independent experiments, where *** = p<0.001. B. Intensity of FoxP3 expression, measured as median fluorescence intensity (MFI) of gated CD4+FoxP3+ lymphocytes. Results are shown as mean values ± SD of n = 4 to 6 mice per group, pooled from at least three independent experiments. doi:10.1371/journal.pone.0025073.g001](https://www.plosone.org/doi/10.1371/journal.pone.0025073.g001)
In vitro suppression assay

Sorted splenic CD4+CD25- cells (Teff), 5×10^4 cells per well, stained with CFSE, from colitic Gαi2-/- or WT mice were incubated with CD4+CD25+ putative Treg from colitic Gαi2-/- or WT mice at Teff:Treg ratios of 2:1, 4:1, 8:1 or Teff alone in 96-well round-bottom plates for 72 h at 37°C in 5% CO₂ in the presence of soluble α-CD3 mAb in Basal Iscove complete medium containing 10% heat-inactivated fetal calf serum, 50 mM 2-mercaptoethanol, 1 mM L-glutamine, and 50 μg/ml gentamicin. Irradiated (25 Gy Cesium-137) T cell-depleted spleen cells from WT mice were used as accessory cells at 2×10^5 cells per well.

Cytokine measurements in supernatants

Cytokine concentrations in supernatants from the suppression assays were measured using a cytometric bead array (CBA) kit, mouse Th1/Th2/Th17 cytokine kit (BD Pharmingen); according to the manufacturer’s instructions. Cytokine levels were quantitated using calibrated standards of each cytokine and analyzed by the CBA software.

Statistical analysis

The Mann-Whitney non-parametric test for unpaired data, the Student t-test or one-way ANOVA (Tukey’s Multiple Comparison Test) were used for comparison between groups. Differences were considered statistically significant at p<0.05.

Results

FoxP3 expression is restricted to CD4+ T cells

The localization of FoxP3 expression within T cell subpopulations in Gαi2-/- mice was analyzed, using mesenteric lymph node (MLN) cells. As illustrated in Table 1, FoxP3+ cells
were restricted to the CD4+ T cell population in the MLN in both precolitic and colitic mice, with up to 90% residing in the CD4+CD25+ T cell population. The CD6+ T cell population had almost no expression of CD25 (<1% positive cells, data not shown) and Foxp3 expression was detected on less than 2% of CD8+ T cells [Table 1].

**Frequency of FoxP3+ lymphocytes in central, peripheral and gut-associated lymphoid tissues**

We and others have reported that precolitic Gsi2−/− mice develop thymic atrophy, a significant decrease in the number of thymocytes, and a higher frequency of mature thymocytes, compared to WT mice [7,24]. As Foxp3 expression is restricted to CD4+ mature single positive thymocytes, we examined the frequencies of CD4+Foxp3+ thymocytes in Gsi2−/− compared to WT mice. Gsi2−/− CD4+ mature thymocytes contained a significantly higher frequency of Foxp3+ cells compared to WT thymocytes (p<0.01) (Fig. 1A). In contrast, there were no significant differences in the frequency of splenic and MLN CD4+Foxp3+ T cells between colitic Gsi2−/− and age-matched WT mice. The frequency of CD4+Foxp3+ T cells was, however, significantly higher (p<0.001) in the colonic lamina propria (LP) of colitic Gsi2−/− mice, compared to the healthy colon of WT controls. In addition, we also analyzed the intensity of expression of Foxp3 within CD4+Foxp3+ cells in the thymus, spleen, MLN, and colonic lamina propria, measured as median fluorescence intensity (MFI). No statistically significant differences were found in these four lymphoid tissues between colitic Gsi2−/− and age-matched WT mice, (Fig. 1B). These data indicate that the spontaneous chronic inflammation in Gsi2−/− mice cannot be explained by a simple quantitative reduction of Treg within total colonic tissues.

However, as it is likely that the function of Treg is related to their distribution within tissues in relation to effector T cells, we further examined their tissue distribution in colonic tissues of WT and colitic Gsi2−/− mice, by immunohistochemistry. In the lamina propria of WT mice, CD4+ T cells were sparse, mostly restricted in the tissue to the level of the crypt bases, and contained few Foxp3+ cells (1–4%, Fig. 2A–B, K–L). In colonic lymphoid patches (CLP) of WT mice, large numbers of CD4+Foxp3+ Treg were observed, restricted to the interfollicular T cell areas (Fig. 2E–F), comprising 10–15% of the total CD4+ T cells in this tissue (Fig. 2L). In colitic Gsi2−/− mice, the distribution was quite different. In the inflamed colon, no discrete CLP with associated clustered CD4+Foxp3+ Treg were observed. Instead, the colonic lamina propria, particularly above the level of crypt bases, was heavily infiltrated by CD4+ cells – a 10× increase over equivalent WT tissues (Fig. 2A–J, K). A significant number of these CD4+ infiltrating cells expressed Foxp3 (Fig. 2K), with a 10–20× increase in the number of CD4+Foxp3+ cells in the basal and upper mucosa, respectively. Similar to the flow cytometric analysis, their frequency in the upper lamina propria were increased 2–3× compared to CD4+ cells in WT colon (Fig. 2L). Thus, the hyperplastic mucosa in established colitis was heavily infiltrated by a ten-fold increase in CD4+ T cells, and the proportion of Foxp3+ cells rose by two- to three-fold. However, this was preceded by a loss of CLP, which, in the WT colon, contain the major proportion of Treg.
High frequencies of CD103-expressing Treg in colitic Gsα2−/− mice

Integrin αECD103β7 contributes to mucosa specific retention of T cells and other cells within epithelia by binding to E-cadherin [25,26]. In addition, CD103 has a possible accessory function for activation of intraepithelial lymphocytes. It has been reported that CD103 is a marker for activated Treg [27]. We therefore investigated the frequency of Treg with CD103 expression in primary, secondary, and gut-associated lymphoid tissues in Gsα2−/− mice. As shown in Fig. 3, the frequency of CD4+FoxP3+ T cells expressing CD103 was significantly increased in Gsα2−/− compared to WT mice in all four tissues studied: thymus, spleen, MLN, and colonic lamina propria.

Treg from colitic Gsα2−/− mice fail to protect against colitis in a transfer model

Our group and others have reported that CD4+ T cells from Gsα2−/− mice undergo altered development and amplified responses to TCR ligation [7,8]. The increase in frequency of Treg among total CD4+ T cells in the thymus and in the inflamed colon of Gsα2−/− mice, compared to WT mice prompted us to investigate the functional activity of the Treg in vivo and in vitro. CD4+CD25− effector T cells from colitic Gsα2−/− mice (KO-Teff), or CD4+CD25− effector T cells from WT mice (WT-Teff) were transferred with or without CD4+CD25+ Treg from Gsα2−/− mice with colitis (KO-Treg) or WT mice (WT-Treg) at a 4:1 Teff:Treg ratio into RAG2−/− recipients. Analysis of the activation phenotype of these transferred CD4+CD25− cells showed that those derived from colitic Gsα2−/− donor spleens contained a significantly higher proportion of cells with a CD4+CD44+CD62L− effector memory phenotype than those derived from WT spleens. Interestingly, the data also show that even in mice of three weeks of age, before the development of colitic symptoms, splenic CD4+ T cells contain significantly higher proportions of effector memory cells (Fig. 4). Five to seven weeks after T cell transfer, mice receiving WT-Teff cells did not develop disease, irrespective of the presence or absence of Treg from either donor. These mice were observed up to 15 or 29 weeks after transfer and did not develop colitis within this time frame (Fig. 5). This is consistent with previous studies demonstrating that, in contrast to the SCID or RAG transfer models on backgrounds other than 129SvEv, in which naïve wild type CD45RBhi T cells induce colitis upon transfer [21], RAG−/− mice on a 129SvEv background, are resistant to colitis induction by wild type cells in the absence of H. hepaticus infection [23].

However, the majority of mice (6/8) receiving KO-Teff cells alone in two separate experiments developed clinical signs of disease (Fig. 5). Co-transfer of KO-Treg or WT-Treg at a 4:1 Teff:Treg ratio at 4×10^5 had little effect on induction of pathology (5/6 and 4/4, respectively, developing colitis). Thus, the KO-Teff cells were highly pathogenic and the pathology induced was unaffected by co-transfer of Treg from either WT or Gsα2−/− mice.

Treg from Gsα2−/− mice are fully functional in vitro

The apparent insufficient regulatory function demonstrated in the in vivo cell transfer model of colitis raises questions regarding the inherent function of the Treg population in the Gsα2-deficient immune system. It has been shown that co-culture of CD4+CD25− Treg with CD4+CD25− effector T cells (Teff) from wild-type mice results in inhibition of the proliferative response of CD4+CD25− effectors [28]. We therefore established an in vitro suppression assay with mixed combinations of Treg and Teff from Gsα2−/− and WT mice at different ratios. Regulation of these Teff responses were analyzed in Teff:Treg co-cultures by cell cycle analysis, using CFSE labeling (Fig. 6). It is apparent from the cell division data (Fig. 6A, B, D) that Treg from both WT (WT-Treg) and Gsα2−/− mice (KO-Treg) were able to suppress proliferation of both WT-Teff and KO-Teff, with the former being more readily suppressed (even at 8:1) than KO-Teff which were suppressed less readily; (at a 4:1 ratio) (Fig. 6A–B). Thus, the in vitro suppressive functions of the Treg populations from the two strains of mice were equivalent. However, this again highlights that KO-Teff were more responsive to signaling through CD3, probably reflecting their pathogenic potential. This was confirmed by comparison of proliferation of the Teff populations alone, measured by CFSE cell cycle analysis (Fig. 6C), demonstrating significantly higher percentages of WT Teff undergoing cell division compared to KO Teff.

Finally, an assessment of Teff cytokines produced in these cultures was made. Supernatants of anti-CD3-activated WT Teff contained relatively low levels of IL-2, IL-4, IL-6, or IFN-γ and it was not possible to define any significant effects on cytokine levels.
mediated by either WT-Treg or KO-Treg (Fig. 7). However, significantly higher levels of cytokines were measured in supernatants of cultures containing activated splenic KO-Teff compared to WT-Teff: 2–3-fold higher for IL-2; 20–60-fold higher for IL-4; 10–20-fold higher for IL-6; and up to 130-fold higher for IFN-$\gamma$ (Fig. 7). It was not possible to define any significant reductions in effector cytokines attributable to addition of Treg to the co-cultures, although a trend towards reduced cytokine production with increasing amounts of Treg in the cultures was noticed. The cytokines IL-10, IL-17 and TNF-$\alpha$ were below the detection limit of our assay.

**Discussion**

Both nTreg and iTreg play a critical role in maintenance of peripheral tolerance by suppressing potential autoimmune responses, while simultaneously regulating inflammatory responses to microbes. Our experiments show that FoxP3-expressing Treg in G$a^i2^{-/-}$ mice are restricted to the CD4$^+$ subpopulation and that these CD4$^+$FoxP3$^+$ T cells are found in higher frequencies in the thymus and colon of colitic G$a^i2^{-/-}$ mice. The high frequency of CD4$^+$FoxP3$^+$ thymocytes is consistent with the G$a^i2$ deficient mice having abnormal thymocyte...

---

**Figure 6.** Treg from G$a^i2^{-/-}$ mice are fully functional in vitro, but KO-Teff are less readily suppressed than WT-Teff. CD4$^+$CD25$^-$ effector T cells (Teff) and CD4$^+$CD25$^+$ regulatory T cells (Treg) were sorted from the spleen of 5 to 8 weeks old colitic G$a^i2^{-/-}$ mice and from age-matched WT littermates, respectively. These effector and regulator cells were mixed at various ratios and in different combinations. CD4$^+$CD25$^-$ Teff cells were pre-stained with CFSE before being added to co-cultures. A–B. In the suppression assay, G$a^i2^{-/-}$ Treg (KO-Treg) or WT Treg (WT-Treg) were added at the indicated ratios with either G$a^i2^{-/-}$ Teff (KO-Teff) or WT Teff (WT-Teff) (5 x 10$^4$ cells per well). The mixtures of cell populations were co-cultured with irradiated T cell depleted splenocytes from WT mice as accessory cells (2 x 10$^5$ cells) and soluble $\alpha$-CD3 mAb for 72 hours. Means ± SEM of cell divisions in the suppression assay from FACS analysis is shown. The results presented are from 4 independent experiments, where ** = $p$$\leq$0.01 and *** = $p$$\leq$0.001. C. Means ± SEM of cell divisions of CFSE WT-Teff and KO-Teff from the wells with Teff only, was analyzed by FACS analysis. The results are based on 4 independent experiments, where *** = $p$$\leq$0.001. D. Representative histograms showing the division of CFSE labeled cells in the absence or presence of KO-Treg or WT-Treg.

doi:10.1371/journal.pone.0025073.g006

**Figure 7.** Cytokine production in the suppression assay co-cultures. Supernatants were harvested after 48 hours and assayed for IL-2, IL-4, IL-6 and IFN-$\gamma$ by CBA analysis. Means ± SEM of cytokine levels from the collected supernatants in two of the triplicate wells are shown. Results presented are from 3 independent experiments, where ** = $p$$\leq$0.01 and *** = $p$$\leq$0.001.

doi:10.1371/journal.pone.0025073.g007
development resulting in an increase in positive selection and aberrant development of CD4+CD25+ T regulatory cells [24]. No differences in intensity of FoxP3 expression by CD4+ T cells were found in the thymus, spleen, MLN and colonic lamina propria of colitic Gαi2−/− mice and age-matched controls, indicating that the phenotype is consistent in both groups.

In the colon, the proportion of isolated CD4+ cells which expressed FoxP3 increased 2–3-fold, compared to WT mice. This might be expected if these putative Treg are migrating into an established site of inflammation in an attempt to restore homeostasis, a phenomenon that has also been observed in rheumatoid arthritis patients [29]. However, it has been suggested that Treg are generated within special DC-containing structures within the colon in response to infiltration by pathogenic CD4+ T cells [30], implying either a structural reservoir of Treg precursors within the colon, or a colonic organized lymphoid structure in which Treg may be generated via DC interactions. To examine structural implications, we derived distribution data using immunohistochemistry. These data show that in the WT mice, the overwhelming majority of colonic FoxP3+ Treg, are indeed associated with organized CLP (and isolated lymphoid follicles (ILF) structures. In accordance with our previous demonstration of regression of Peyer’s patches in Gαi2−/− mice prior to colitis [2], CLP and ILF were not observed in inflamed Gαi2−/− colons but the numbers of lamina propria CD4+FoxP3+ cells increased in inflammation, with their frequency within the total CD4+ population increasing, based on both flow cytometry and immunohistochemistry data. We speculate that CLP represent the WT equivalent of the minimal DC structures seen in the RAG2−/− transfer model [30] and that they may constitute reservoirs in which Treg either accumulate and/or are generated, although this requires further investigation. Regardless of this interpretation, CD4+ cells with a Treg phenotype clearly accumulate in significantly increased frequency within the inflamed colonic mucosa.

It is possible that the higher frequency of FoxP3+ cells in the colonic lamina propria of colitic Gαi2−/− mice may be a consequence of ongoing inflammation, as there was no significant difference in the frequency of CD4+FoxP3+ T cells at other peripheral sites, such as spleen and MLN, between Gαi2−/− and WT mice. These findings concur with reports from human disease - in patients with active IBD, the number of FoxP3+ cells in the affected intestinal mucosa correlates with disease activity [31,32]. Our data show that CD4+FoxP3+ Treg, in both central and peripheral lymphoid tissue in colitic Gαi2−/− mice have a substantially higher frequency of cells expressing CD103, compared to controls. CD103 have been reported to be a activation marker for Treg [33]. The CD4+FoxP3+CD103− subset expresses CTLA-4; suppresses T cell proliferation in vitro, and protects mice from colitis in the severe combined immunodeficient (SCID) transfer model in vivo [33]. Integrin αECD103β7 can therefore be regarded as a marker for activated regulatory T cells, including those operating at the mucosal barrier. It is possible that in the steady state, Treg efficiently home to lymph nodes, expand and accumulate where cognate antigens are present. This basal level of activity prevents priming of autoreactive T cells and maintains immune homeostasis. However, when this first line of protection fails and barrier breakdown, tissue destruction and inflammation occur, changes in the local microenvironment enable further activation of T cells into Treg with high expression of CD103, allowing their traffic to affected tissues [34].

We have shown that Treg from colitic Gαi2−/− mice are as potent as WT Treg in inhibiting the proliferative response of both WT-Teff and KO-Teff following polyclonal TCR-mediated stimulation in vitro, although KO-Teff were less inhibited by either Treg population compared to WT-Teff. The crucial finding of our experiments is that Gαi2−/− Treg are fully functional and there is no endogenous Gαi2-related defect. Nonetheless, these apparently potent Gαi2−/− Treg, paradoxically, were only partially protective against colitis in the RAG2−/− transfer model. However, the protective effect of Gαi2−/− Treg in vivo was comparable to WT Treg. On the basis of the in vitro and in vivo data, we argue that the dysregulated immune activity in this model is a product of heightened effector cell activity, and not of reduced Treg function, within the colitic lesion.

Our present and previous data by others clearly demonstrate that T effectors from Gαi2−/− mice are more pro-inflammatory [8]. This is presumably a reflection of the phenotype of the cells we have used as effectors. The Gαi2−/− Teff population comprised many more cells with a CD4+CD62L− CD44+ effector memory phenotype than WT Teff, which are more easily activated to proliferate and less susceptible to regulation by Treg. In addition, IL-6, one of the proinflammatory cytokines secreted at high levels by KO-Teff in this study, has been shown to enhance the resistance of T effector cells to the suppressive effects of Tregs [35,36]. With regard to this possibility, administration of IL-6R mAb to SCID mice, after transfer of CD45RBhi T cells, confers protection from colitis [37], and IL-6-deficient mice have been shown to be less susceptible to colitis [38]. Finally, cells with this phenotype can actively suppress the induction of iTreg by cell contact and secreted factor-mediated mechanisms [39]. Even in young mice, before the age of onset of frank colitis, Gαi2−/− CD4+ T cells are pushed towards this phenotype. It seems likely, then, that the Gαi2−/− deletion drives the differentiation of CD4+ T cells towards this easily activated, not readily regulated, effector memory phenotype, which proliferate to bacterial antigens in the Gαi2−/− colon with a potentially defective epithelial barrier [5], and actively suppress the induction of appropriate numbers of inducible regulatory T cells [39]. In addition, defective chemokine receptor signaling within the Gαi2−/− environment may reduce the infiltration of effective numbers of Treg.

In conclusion, Gαi2−/− Treg that are functionally active in vitro are enriched in the inflamed colon in Gαi2−/− mice, but are unable to regulate the highly potent Gαi2−/− effector T cells, which we demonstrated to be significantly more resistant to suppression by either WT or Gαi2−/− Treg, compared to WT effector T cells. Further studies are in progress to investigate the relative kinetics of mucosal Teff and Treg infiltration during pathogenesis.

Author Contributions
Performed the experiments: Y-YG. Analyzed the data: Y-YG PB EH. Wrote the paper: Y-YG PB EH. Contributed methods/protocols/technical supports: SR.

References
1. Hornquist GE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, et al. (1997) G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 158: 1068–1077.
2. Ohman L, Franzen L, Rudolph U, Birnbaumer L, Hornquist EH (2002) Regression of Peyer’s patches in G alpha i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 158: 1068–1077.
3. Ohman L, Franzen L, Rudolph U, Harriman GR, Hultgren Hornquist E (2000) Immune activation in the intestinal mucosa before the onset of colitis in Gαi2-deficient mice. Scand J Immunol 52: 80–90.
4. Dalwadi H, Wei B, Schrage M, Spicher K, Su TT, et al. (2003) B cell developmental requirement for the G alpha i2 gene. J Immunol 170: 1707–1715.
5. Saha C, Nigam SK, Denker BM (1998) Involvement of Galphai2 in the maintenance and biogenesis of epithelial cell tight junctions. J Biol Chem 273: 21629–21633.

6. He J, Gurunathan S, Iwasaki A, Ash-Shaheed B, Kelsall BL (2000) Primary role for Gα protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. J Exp Med 191: 1605–1610.

7. Elgratt K, Bjursten M, Willen R, Bland PW, Hornquist EH (2007) Aberrant T-cell ontology and defective thymocyte and colonic T-cell chemotactic migration in colitis-prone Galphai2-deficient mice. Immunology 122: 199–209.

8. Huang TT, Zoung Y, Dalwadi H, Chuang C, MicheI MC, et al. (2005) TCR-mediated hyper-responsiveness of autoimmune Galphai2(−/−) mice is an intrinsic naive CD4+ T cell disorder selective for the Galphai2 subunit. Int Immunol 15: 1359–1367.

9. Halvetry OH, Berglund M, Bjursten M, Hultgren Hornquist E (2006) Serum interleukin-1 receptor antagonist is an early indicator of colitis onset in Galphai2-deficient mice. World J Gastroenterol 12: 621–624.

10. Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206: 232–259.

11. Mackay IR (2000) Science, medicine, and the future: Tolerance and autoimmunity. BMJ 321: 93–96.

12. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742.

13. Weiner HL (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207–214.

14. Mogayl OA, Collins JW, Workman CJ (2008) How regulatory T cells work. Eur J Immunol 38: 330–336.

15. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523–532.

16. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T (2009) Regulatory T cells: how do they suppress immune responses? Int Immunol 21: 1105–1111.

17. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.

18. Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T cell-mediated suppression by dendritic cells. Science 299: 1057–1061.

19. Dioudin K, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ regulatory T cells. Nat Immunol 4: 337–342.

20. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061.

21. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.

22. Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T cell-mediated suppression by dendritic cells. Science 299: 1057–1061.

23. Maloy KJ, Salama L, Cahill R, Dougan G, Saunders NJ, et al. (2003) CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197: 111–119.

24. Zhang Y, Finegold MJ, Jin Y, Wu MX (2005) Accelerated transition from the double-positive to single-positive thymocytes in Gα i2-deficient mice. Immune Netw 17: 233–243.

25. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, et al. (1994) Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αβ T cell beta 7 integrin. Nature 372: 190–195.

26. Karczewski PJ, Bowden SJ, Green SJ, Kilkhus P (1995) Recognition of E-cadherin on epithelial cells by the mycosal T cell integrin alpha M beta 2. Eur J Immunol 25: 852–856.

27. Simonetta F, Chiabi A, Cordery C, Urrutia A, Girault I, et al. (2010) Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol 40: 2528–2538.

28. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172: 6519–6523.

29. Leipe J, Skaperko A, Lipsky PE, Schulze-Koops H (2005) Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 7: 93.

30. Leithauser F, Meinhart-Krajina T, Fink K, Wotschke B, Moller P, et al. (2006) Foxp3-expressing CD103+ regulatory T cells accumulate in dendritic cell aggregates of the colonic mucosa in murine transfer colitis. Am J Pathol 168: 1899–1908.

31. Holta VK, Sipponen T, Westerholm-Omio M, Kocibahrski G, Salo H, et al. (2008) IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis 14: 1175–1184.

32. redhead L, Loddenkemper C, Mundt P, Berg E, Giese T, et al. (2005) Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868–1878.

33. Lehmann J, Huesn J, de la Rosa M, Masunya F, Kretschmer U, et al. (2002) Expression of the integrin alpha E beta 7 identifies unique subsets of CD25+ as well as CD25+ regulatory T cells. Proc Natl Acad Sci U S A 99: 13031–13036.

34. Bluestone JA, Tang Q (2005) How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol 17: 638–642.

35. Goodmam WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, et al. (2009) IL-6 signaling in psoaiaaxis prevents immune suppression by regulatory T cells. J Immunol 183: 3170–3176.

36. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033–1036.

37. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878–4882.

38. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, et al. (2001) CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. Curr Opin Immunol 13: 251–253.

39. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.

40. Gurna AM, Stack W, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523–532.